| abstract |
Disclosed are pharmaceutical compositions of hepatitis C virus protease inhibitors suitable for oral administration by liquid- or semi-solid-filled capsules, and for inhibiting hepatitis C virus (HCV) replication, Also a method of using this composition for the treatment of HCV infection. The liquid- or semi-solid-pharmaceutical composition of the invention comprises a compound of formula I, or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable lipids and a hydrophilic surfactant. Included. |